Novo Nordisk A/S (NOVO-B) Fair Value & Analysis
Healthcare · DK · Market cap 1.3T DKK
Fair value as of: Jul 7, 2026
From 26 valuation models · updated 10 days ago
Fair value updated Jul 7, 2026, revised from kr 542.67 to kr 409.46 (−24.5%) since Jun 24, 2026. Share price +19.8% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 223.78 – kr 435.27 · fair‑value band kr 206.04 – kr 565.28 · the kr 335.80 price screens below the kr 409.46 fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Novo Nordisk A/S (NOVO-B) currently trades at kr 335.80, while our model-based Fair Value estimate is kr 409.46, implying the stock looks roughly 21.9% undervalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Novo Nordisk A/S generated revenue of 328B DKK at a net margin of 37.2%. Revenue grew 24.0% year over year. It earns a return on equity of 71.4%. Net debt stands at 104B DKK. Fundamentals as of Jul 7, 2026
Our scenario range runs from kr 206.04 (bear case) to kr 565.28 (bull case); at kr 335.80, the current price sits within that range. The share trades about 34% below its 52-week high and 55% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at 22%, NOVO-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Novo Nordisk A/S reported revenue of kr 309B in FY2025 versus kr 141B in FY2021, a compound +21.7%/yr. Reported net income was kr 102B in FY2025, compounding +21.0%/yr from FY2021.
Is NOVO-B fairly valued? → Check now
Recent news
- How Microsoft (MSFT) Is Deepening Its Enterprise AI Moat With a $2.5 Billion Customer Deployment Initiative
- Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
- Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share
- Novo Nordisk A/S - share repurchase programme
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc 4AB | €186.15 | €93.56 | -50% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| Novartis AG NVSN | 2,601 MXN | 1,897 MXN | -27% |
| AstraZeneca PLC ZEG | €160.70 | €128.63 | -20% |
| Amgen Inc AMGN | $344.72 | $261.17 | -24% |
| Gilead Sciences, Inc GILD34 | R$337.84 | R$214.60 | -36% |
| Pfizer Inc PFE | C$11.60 | C$8.86 | -24% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novo Nordisk A/S (NOVO-B) undervalued?
What is the fair value of NOVO-B?
What is the quality score of NOVO-B?
What is the revenue of Novo Nordisk A/S (NOVO-B)?
What is the net profit margin of NOVO-B?
Does Novo Nordisk A/S pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Novo Nordisk A/S analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.